Our review will focus on the implications of TGFβ signaling and regulation of this pathway using modifications of cell cycle/proliferation checkpoint inhibitors known as cyclin-dependent kinase (CDK) inhibitors, used to treat hormone receptor and human epidermal growth factor receptor 2 (HER2) positive and negative advanced breast cancer. This evidence concerns the gene NR4A1 and breast cancer.